t=0 min 180 ≤ t ≤ 240 min
  No addition No addition Sorafenib Regorafenib
kca (μM O2 min-1 mg-1) 0.30 ± 0.08 (n=4) 0.21 ± 0.05 (n=9) 0.19 ± 0.01 (n=5) 0.19 ± 0.02 (n=5)
ATPb (pmol mg-1) 167 56 ± 23 (n=6) 47 ± 40 (n=4) 41 ± 22 (n=4)
AMC peak areac (arbitrary unit mg-1 ÷ 103) 71 104 ± 41 (n=4) 96 ± 41 (n=3) 47 ± 21 (n=3)
Urea synthesisd (mg/dL mg-1) 0.25 ± 0.01 (n=6) 0.16 ± 0.03 (n=6) 0.17 ± 0.03 (n=4) 0.17 ± 0.06 (n=5)
aFive individual experiments involving five mice were done for each compound. The concentration of sorafenib was 2.5 μM in three experiments and 50 μM in two experiments. The concentration of regorafenib was 5 μM in three experiments and 50 μM in two experiments. The in vitro incubation with the drugs was up to 6 h. There was no statistical significance between the untreated and treated pairs. bFour individual experiments involving four mice were done for each compound. The concentration of sorafenib was 2.5 μM in three experiments and 50 μM in one experiment. The concentration of regorafenib was 5 μM in three experiments and 50 μM in one experiment. The in vitro incubation with the drugs was 180 to 240 min. There was no statistical significance between the untreated and treated pairs (p>0.556). cThree individual experiments involving three mice were done for each compound. The concentration of sorafenib was 2.5 μM in two experiments and 50 μM in one experiment (Figure 4). The concentration of regorafenib was 5 μM in two experiments and 50 μM in one experiment (Figure 4). The in vitro incubation with the drugs was 180 to 240 min. There was no statistical significance between the untreated and treated pairs (p>0.114). dFor sorafenib, four individual experiments involving four mice were done. The concentration of sorafenib was 2.5 μM in two experiments and 50 μM in two experiments. For regorafenib, five individual experiments involving five mice were done. The concentration of regorafenib was 5 μM in three experiments and 50 μM in two experiments. The in vitro incubation with the drugs was 180 min. There was no statistical significance between the untreated and treated pairs (p>0.429). Values are mean ± SD
Table 1: Effects of sorafenib and regorafenib on liver tissue respiration, ATP content, caspase activity, and urea synthesis.